


Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	09/857,000
(use as many sheets as necessary)				Filing Date	September 7, 2001
Sheet 1 of 1				First Named Inventor	PHILIPPE CLAIR ET AL.
				Group Art Unit	1656
				Examiner Name	KAM, CHIH MIN
				Attorney Docket Number	03-520

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/CMK/		ROUSSELLE, C., ET AL., "New Advances in the Transport of Doxorubicin Through The Blood-Brain-Barrier by a Peptide Vector-Mediated Strategy", Mol. Pharmacol., 57, 879 (2000).	abstract only
		ROUSSELLE, C., ET AL., "Enhanced Delivery of Doxorubicin into the Brain Via a Peptide-Vector-Mediated Strategy: Saturation Kinetics and Specificity", J. Pharmacol. Exp Ther., 296, 124 (2001).	abstract only
		BLANC, E., ET AL., "Peptide-Vector Strategy Bypasses P-Glycoprotein Efflux, and Enhances Brain Transport and Solubility of Paclitaxel", Anticancer Drugs., 15, 947-954 (2004). 947 - 954 (2004)	
		ROUSSELLE, C., ET AL., "Improved Brain Delivery of Benzylpenicillin with a Peptide-Vector-Mediated Strategy", J Drug Target., 10, 309 (2002). 309 - 315	
↓		TEMSAMANI, J., ET AL., "Improved Brain Uptake and Pharmacological Activity Profile of Morphine-6-Glucuronide Using a Peptide Vector-Mediated Strategy", J Pharmacol. Exp Ther., 313, 712, (2005).	abstract only
/CMK/		ROUSSELLE, C., ET AL., "Improved Brain Uptake and Pharmacological Activity of Dalargin Using a Peptide-Vector Mediated Strategy", J Pharmacol. Exp Ther., 308, 371 (2003).	abstract only

Examiner Signature	/Chih-Min Kam/	Date Considered	03/22/2007
--------------------	----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.